{"title":"重度抑郁症的精神药理学研究进展。","authors":"Laith Alexander, Allan H Young","doi":"10.1192/bja.2022.14","DOIUrl":null,"url":null,"abstract":"<p><p>This review highlights some of the recent advances in the psychopharmacology of Major Depressive Disorder (MDD). We synthesise evidence on emerging pharmacological therapies targeting the serotonergic system, before exploring several novel treatment targets: the glutamatergic system, the GABAergic system, and inflammation. When describing new treatment avenues, we examine the evidence base and how far these new treatments are from routine practice.</p>","PeriodicalId":9336,"journal":{"name":"BJPsych Advances","volume":"58 1","pages":"117-130"},"PeriodicalIF":1.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617086/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recent Advances in the Psychopharmacology of Major Depressive Disorder.\",\"authors\":\"Laith Alexander, Allan H Young\",\"doi\":\"10.1192/bja.2022.14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This review highlights some of the recent advances in the psychopharmacology of Major Depressive Disorder (MDD). We synthesise evidence on emerging pharmacological therapies targeting the serotonergic system, before exploring several novel treatment targets: the glutamatergic system, the GABAergic system, and inflammation. When describing new treatment avenues, we examine the evidence base and how far these new treatments are from routine practice.</p>\",\"PeriodicalId\":9336,\"journal\":{\"name\":\"BJPsych Advances\",\"volume\":\"58 1\",\"pages\":\"117-130\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617086/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BJPsych Advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1192/bja.2022.14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/4/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJPsych Advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1192/bja.2022.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Recent Advances in the Psychopharmacology of Major Depressive Disorder.
This review highlights some of the recent advances in the psychopharmacology of Major Depressive Disorder (MDD). We synthesise evidence on emerging pharmacological therapies targeting the serotonergic system, before exploring several novel treatment targets: the glutamatergic system, the GABAergic system, and inflammation. When describing new treatment avenues, we examine the evidence base and how far these new treatments are from routine practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
